Browsing Tag
BRCA2 mutation
1 post
Johnson & Johnson expands AKEEGA’s reach with FDA nod in BRCA2-mutated metastatic castration-sensitive prostate cancer
Johnson & Johnson’s AKEEGA secures FDA approval for BRCA2-mutated prostate cancer, reshaping early-stage treatment and signaling a shift toward genomic-first therapy.